Generic NERLYNX crossed a market-share threshold in China, forcing a $2.1 million royalty writedown that pushed revenue below expectations even as earnings cleared consensus. Management raised full-year net income guidance to $20 million to $22 million and says delayed ex-US partner shipments land in the fourth quarter.
Latest Activity
PBYI Coverage
3 High-Flying Stocks Under $10 to Buy Hand Over Fist Right Now
There’s a small portion of my portfolio I allocate toward companies I’d put in the “higher risk” bucket. For me, that means small caps and companies that trade either under the radar…
Sizzling Buy-Rated Biotechs Highlight 5 Top Stocks Under $10
These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. While not suited for all investors, they are not penny stocks with…
Tuesday’s Top Analyst Upgrades and Downgrades: Applied Materials, Aurora Cannabis, Chewy, Coinbase, Kinder Morgan, Macy’s, Qualcomm, Wells Fargo and More
Tuesday's top analyst upgrades and downgrades included Applied Materials, Aurora Cannabis, Chewy, Coinbase Global, Kinder Morgan, Macy's, Qualcomm and Wells Fargo.
Why These Breast Cancer Study Results Look So Promising
Puma Biotechnology shares made a handy gain early on Thursday after the company presented updated results from its Phase 2 Summit clinical trial of neratinib at the 2019 San Antonio Breast Cancer…
Top Analyst Upgrades and Downgrades: Anthem, Ciena, Dollar General, Encana, Lennar, Lululemon, Sage Therapeutics, Target, Tesla, Trade Desk, Yext and More
Friday's top analyst upgrades and downgrades included Anthem, Ciena, Dollar General, Encana, Lennar, Lululemon Athletica, Sage Therapeutics, Target, Tesla, Trade Desk and Yext.
Top Analyst Upgrades and Downgrades: Apollo, BlackRock, Cloudflare, Green Plains, Microsoft, Oracle, Target, TJX and More
Tuesday's top analyst upgrades, downgrades and initiations included Apollo Global Management, BlackRock, Cloudflare, Green Plains, Microsoft, Oracle, Target and TJX Companies.
What This Recent FDA Move Could Mean for Breast Cancer Patients With Brain Metastases
Puma Biotechnology shares jumped early Wednesday after FDA news about Puma’s breast cancer treatment. However, Puma shares quickly fell off from this FDA sugar high.
Top Analyst Upgrades and Downgrades: American Air, BlackBerry, Mallinkrodt, PG&E, RingCentral, Southwest Airlines, Yeti and More
Stocks were indicated to open lower on Monday after weekend news that sounds like a China trade deal is not on the way very soon. Investors have been forced to see…
Puma Biotech, General Electric Plummet into Friday’s 52-Week Low Club
General Electric, Encana Energy, Puma Biotechnology, and Kraft Heinz all posted new 52-week lows Friday.
Top Analyst Upgrades and Downgrades: Abiomed, Allscripts, Apple, Carbonite, Kraft Heinz, L3, Southern Copper, Starbucks, VeriSign, XPO and More
Stocks were indicated to open higher on China trade deal hopes and after a stronger nonfarm payrolls report. While the stock market has bounced handily from the lows at the end…
Can Puma Biotechnology Break In to Europe?
Puma Biotechnology shares were climbing on Tuesday after the company announced that it expects a positive outcome in Europe.
Top Analyst Upgrades and Downgrades: AMC, Alkermes, Echostar, Kohls, L Brands, US Bancorp, Sarepta Therapeutics and More
The top analyst upgrades, downgrades and other research calls from Friday included AMC, Alkermes, Echostar, Kohls, L Brands, US Bancorp and Sarepta Therapeutics.
Breast Cancer Drug Can Bring Exponential Sales Growth for Puma Biotechnology
The world of biotech can be a rags-to-riches story for companies that build up a drug candidate and secure FDA approval for that drug. And the larger the drug target group is,…
Top Analyst Upgrades and Downgrades: Albermarle, American Airlines, Ellie Mae, Johnson & Johnson, Mallinckrodt, Mylan, NetApp, Southwest Air and More
The top analyst upgrades, downgrades and other research calls from Thursday include Albermarle, American Airlines, Ellie Mae, Johnson & Johnson, Mallinckrodt, Mylan, NetApp and Southwest Airlines.
Why Analysts Are Slashing Their Targets for Puma Biotechnology
Puma Biotechnology saw its shares take a dive on Wednesday following regulatory events in Europe for its breast cancer treatment.